US4501744A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted-aza-cytosine compounds and anti-viral uses thereof
Assignee: Syntex USA LLC
•
Filing: 1983-07-28
•
Granted: 1985-02-26
•
Expires: 2003-07-28
Abstract
Abstract Nucleoside analogues having a ring-open structure, of general formula: ##STR1## where R and R' may be hydrogen, silyl groups, substituted alkyl groups, benzyl groups and the like, and X is an optionally substituted pyrimidine or triazine base, exhibit anti-viral activities e.g. against herpes simplex virus and cytomegalo-virus at non-toxic levels.
Inventors
- 👤 Kelvin K. Ogilvie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 10:38
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/47; C07D239/52; C07D239/54; C07D239/545; C07D239/553; C07D251/00; C07D251/02; C07D251/12; C07D251/14; C07D251/16; C07D473/00; C07D473/02; C07D473/18; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804; C07F9/00; C07F9/02; C07F9/547; C07F9/645; C07F9/6509; C07F9/6512; C07F9/6561; C07F9/65616; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
6 words
5-aza-1-[[1-hydroxymethyl-(2-hydroxy)ethoxy]methyl]cytosine and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
6 words
5-aza-1-[[1-hydroxymethyl-(2-hydroxy)ethoxy]methyl]cytosine and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
1 words
5-aza-1-[[1-hydroxymethyl-(2-hydroxy)ethoxy]methyl]cytosine.
Claim 4
Dependent Claim
1 words
5-aza-1-[[1-hydroxymethyl-(2-hydroxy)ethoxy]methyl]cytosine.
Claim 5
Dependent Claim
24 words
A pharmaceutical composition suitable for administration to a mammal for treatment of viral infections, comprising as active ingredient a compound according to claim 1.
Claim 6
Dependent Claim
30 words
A pharmaceutical composition active in combatting herpes viral infections and consisting essentially of the effective amount of a compound according to claim 1, in admixture with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
30 words
A method of treating herpes viral infection in a mammal, which comprises administering to the infected mammal an effective, non-toxic amount of a compound or salt according to claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-02-26 | 1988-08-27 | 1989-02-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-02-26 | 1992-08-27 | 1993-02-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-02-26 | 1996-08-27 | 1997-02-26 | $7700.00 | Window Closed / Lapsed |